JUNE 12, 2024
Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens Seqens, an integrated global player in solutions and ingredients for
JUNE 10, 2024
Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity Biophytis announces that it has submitted an
JUNE 7, 2024
Combined General Meeting of June 24, 2024 Biophytis will hold its Combined General Meeting (CGM) on June 24, 2024 at 2pm at Sorbonne Université –
MAY 14, 2024
Biophytis announces the design of its phase 2 OBA clinical study in obesity Biophytis announces the design of its phase 2 OBA clinical study in
APRIL 29, 2024
Biophytis is deploying its partnership strategy in obesity Biophytis today the implementation of a dedicated strategy for partner search in obesity. Biophytis is continually working
APRIL 24, 2024
Biophytis Announces Transfer of ADSs to OTC Market ADSs delisted from Nasdaq, which will result in meaningful savings ADSs transferred to OTC Pink market; Company
APRIL 19, 2024
Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program Biophytis annouces that it will change the ratio of its American Depositary Shares (the
APRIL 18, 2024
Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity IND to be filed with the FDA in the coming
APRIL 15, 2024
Biophytis files a patent application and strengthens its intellectual property in obesity Biophytis announces the filing of a patent application in the treatment of obesity,
APRIL 8, 2024
Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) Promising preclinical results obtained in obesity support the OBA Phase 2 clinical study